Literature DB >> 28672080

Ki67, CD105, and α-SMA expressions better relate the binary oral epithelial dysplasia grading system of World Health Organization.

Amol Ramchandra Gadbail1, Minal S Chaudhary2, Sachin C Sarode3, Madhuri Gawande2, Sheetal Korde4, Satyajit Ashok Tekade5, Shailesh Gondivkar6, Alka Hande2, Rupesh Maladhari2.   

Abstract

BACKGROUND: The binary system of oral epithelial dysplasia (OED) has never been investigated with reference to the carcinogenesis-related biomarkers. Hence, Ki67, CD105, and α-SMA immune-expressions were studied in oral potentially malignant disorders (OPMDs) to assess their relationship with the binary OED grading system of World Health Organization.
METHODS: The study was carried out on paraffin-embedded tissues of 30 normal oral mucosa (NOM) and 140 OPMD cases. OPMD cases were classified into two groups "no/questionable/hyperkeratosis/mild"=low-risk epithelial dysplasia (LRED) and "moderate or severe"=high-risk epithelial dysplasia (HRED). The immunohistochemistry was carried out to evaluate the expression of Ki67, CD 105, and α-SMA antigen.
RESULTS: According to the binary grading system of WHO, 69 (49.28%) cases were LRED, while 71 (50.71%) case showed HRED. There was significant increase in Ki67 labeling index (LI) from NOM to LRED to HRED (P=.000). Similarly, mean vascular density (MVD) also increased significantly from NOM to LRED to HRED (P=.000). The α-SMA expression was significantly higher in HERD compared to LRED and NOM (P=.000). A positive correlation was noted among Ki67 LI, MVD, and α-SMA expressions in NOM, LRED, and HRED (P=.000).
CONCLUSION: The expressions of ki67, CD105, and α-SMA markers compliment binary grading system of OED in OPMDS, thus justifying its use in clinical practice.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD105; Ki67; areca nut; oral epithelial dysplasia; oral submucous fibrosis; α-SMA

Mesh:

Substances:

Year:  2017        PMID: 28672080     DOI: 10.1111/jop.12612

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  7 in total

1.  Nesfatin-1 is a potential diagnostic biomarker for gastric cancer.

Authors:  Xiao-Qing Wang; Yan Zheng; Pei-Fei Fang; Xian-Bing Song
Journal:  Oncol Lett       Date:  2019-12-10       Impact factor: 2.967

2.  Ki67, CD105, and α-SMA Expression Supports Biological Distinctness of Oral Squamous Cell Carcinoma Arising in the Background of Oral Submucous Fibrosis.

Authors:  Amol Ramchandra Gadbail; Sheetal Korde; Minal S Chaudhary; Sachin C Sarode; Shailesh M Gondivkar; Ravi Dande; Satyajit Ashok Tekade; Monal Yuwanati; Alka Hande; Shankargouda Patil
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

3.  Ki67 Labelling Index predicts clinical outcome and survival in oral squamous cell carcinoma.

Authors:  Amol Ramchandra Gadbail; Sachin C Sarode; Minal S Chaudhary; Shailesh M Gondivkar; Satyajit Ashok Tekade; Monal Yuwanati; Shankargouda Patil
Journal:  J Appl Oral Sci       Date:  2021-03-01       Impact factor: 2.698

4.  Non-specific Chief Complaints Among Oral Submucous Fibrosis Patients at Outpatient Department and Pan Shop at Rural Region in India.

Authors:  Rohan Sachdev; Kriti Garg; Samiksha Shwetam; Akash Srivastava
Journal:  J Int Soc Prev Community Dent       Date:  2021-07-30

Review 5.  Diagnostic Utility of Cytokeratin 17 Expression in Oral Squamous Cell Carcinoma: A Review.

Authors:  Ankita Gyanchandani; Samarth Shukla; Sunita Vagha; Sourya Acharaya; Ravindra P Kadu
Journal:  Cureus       Date:  2022-07-19

6.  Serum aflatoxin B1 antibody titer, percent hemolysis and transaminases in oral submucous fibrosis.

Authors:  Rahul R Bhowate; Vidya K Lohe; Mrunal Ghusaji Meshram; Suwarna B Dangore
Journal:  J Oral Maxillofac Pathol       Date:  2021-05-14

Review 7.  Molecular markers associated with potentially malignant oral lesions (Review).

Authors:  Oana Mihaela Condurache Hritcu; Ana Emanuela Botez; Doinita Temelie Olinici; P Onofrei; Laura Stoica; V B Grecu; Paula Mihaela Toader; Laura Gheucă-Solovăstru; Elena Carmen Cotrutz
Journal:  Exp Ther Med       Date:  2021-06-04       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.